On the 13th, medical aesthetic company Clashes announced that it recorded 87.2 billion won in sales and 37.2 billion won in operating profit in the first quarter on a consolidated basis. Revenue rose 13% year-on-year, and operating profit fell 4.1%. The operating margin reached 42.7 percent.
Clash expects cascading growth potential starting in the second quarter. Quad-Say products have been released in countries such as the U.S. and Thailand following Korea, and in Europe, the spread of ultra-former and ball-newmer around major countries is in full swing, leading to sales growth.
"In Japan, we are waiting for orders for large clinic chains, and at home and abroad, brand marketing to revitalize consumables is strengthened, raising expectations for repeated sales growth," a Clash official said. "In China, the possibility of Volnewmer's approval within this year is also increasing."
